GLP-1
Tirzepatide is arguably the most significant advance in obesity pharmacology in a generation. Marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, tirzepatide is the world's first approved dual GIP/GLP-1 receptor agonist—a novel mechanism that consistently outperforms everything that came before it. In
GLP-1
Semaglutide has reshaped modern medicine. Originally developed for type 2 diabetes, this GLP-1 receptor agonist is now one of the most prescribed medications globally — sold as Ozempic for diabetes, Wegovy for weight loss, and Rybelsus as an oral formulation. With landmark clinical trials, groundbreaking cardiovascular data, and a contentious compounding
GLP-1
Retatrutide (LY3437943) is a next-generation weight loss medication unlike anything before it. While semaglutide targets one receptor and tirzepatide targets two, retatrutide simultaneously activates three: GLP-1, GIP, and glucagon. This triple-receptor approach has produced the highest weight loss numbers ever recorded in a Phase 3 obesity trial — 28.7% average
GLP-1
A new era in obesity medicine is taking shape — and it goes by the name CagriSema. Developed by Novo Nordisk, CagriSema combines two distinct peptide therapies — cagrilintide, a long-acting amylin analogue, and semaglutide, the active ingredient in Ozempic and Wegovy — into a single weekly injection. The result? Phase 3 clinical
GLP-1
CagriSema — the combination of cagrilintide and semaglutide — delivered over 20% weight loss in phase 3 trials. Here is what the science says, how it compares to tirzepatide, and what patients need to know.
GLP-1
Tirzepatide has quickly become one of the most talked-about medications in metabolic health — and for good reason. Whether you know it as Mounjaro (for type 2 diabetes) or Zepbound (for weight management), this dual-action molecule is rewriting what we thought was possible with pharmaceutical weight loss. Patients are losing 20%
GLP-1
GLP-1
Liraglutide has been reshaping metabolic medicine since its FDA approval in 2010. Sold under the brand names Victoza (for type 2 diabetes) and Saxenda (for chronic weight management), it was the first once-daily GLP-1 receptor agonist to demonstrate cardiovascular mortality benefits in a large outcomes trial. Now, in 2026, generic
GLP-1
Retatrutide is shaping up to be the most powerful weight-loss drug ever developed. With Phase 3 trial data showing nearly 29% mean body weight reduction — numbers that rival bariatric surgery — Eli Lilly's triple-agonist candidate has captured the attention of physicians, patients, and investors alike. But what exactly is
GLP-1
Tirzepatide has quickly become one of the most talked-about medications in modern medicine — and for good reason. Marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, this weekly injection has produced weight loss results that surpass virtually every other pharmacological option available. But what exactly is
GLP-1
Semaglutide has reshaped modern medicine. From controlling blood sugar in people with type 2 diabetes to producing dramatic weight loss in people with obesity, this once-weekly injectable—and now pill—has become one of the most prescribed medications in the world. Sold under the brand names Ozempic, Wegovy, and Rybelsus,
GLP-1